摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(4-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid | 66183-72-0

中文名称
——
中文别名
——
英文名称
1-[(4-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid
英文别名
1-(4-Fluorobenzyl)-5-oxoproline
1-[(4-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid化学式
CAS
66183-72-0
化学式
C12H12FNO3
mdl
——
分子量
237.231
InChiKey
HVGUBDIPIWRNTI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    57.6
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • [EN] HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS<br/>[FR] SULFONES HÉTÉROCYCLIQUES COMME MODULATEURS DE ROR GAMMA
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2018071620A1
    公开(公告)日:2018-04-19
    There are described RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ Gamma activity, for example, autoimmune and/or inflammatory disorders.
    这里描述了公式(I)的RORγ调节剂,或其立体异构体、互变异构体、药用可接受的盐、溶剂化物或前药,其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ Gamma活性的方法和治疗因调节RORγ Gamma活性而可从治疗中受益的疾病或病症的患者的方法中是有用的,例如,自身免疫和/或炎症紊乱。
  • [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
    申请人:HAPLOGEN GMBH
    公开号:WO2018050631A1
    公开(公告)日:2018-03-22
    The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    本发明涉及一般式(I)的新化合物,其中X和R1至R4基团的含义如描述和索赔中所述,制备这些化合物的方法以及它们作为治疗、预防或改善病毒感染的用途,以及用于治疗、预防或改善与PLA2G16相关的疾病的用途。
  • Enantiometric iodobenzamides
    申请人:THE VANDERBILT UNIVERSITY
    公开号:EP0320630A1
    公开(公告)日:1989-06-21
    Novel iodine-substituted benzamide derivatives of formula I wherein R¹ is a hydrogen atom, a lower alkyl group consisting of 1 to 4 carbon atoms, a cycloalkyl group consisting of 3 to 7 carbon atoms, an alkenyl group consisting of 2 to 4 carbon atoms, an alkynyl group consisting of 2 to 4 carbon atoms, a phenyl group, a halogen substituted phenyl group, or an enantiomer or pharmaceutically suitable salt thereof, exhibit high blocking activity and specifity for the dopamine D-2 receptor.
    式I的新取代苯甲酰胺衍生物,其中R¹是氢原子,由1至4个碳原子组成的较低烷基基团,由3至7个碳原子组成的环烷基基团,由2至4个碳原子组成的烯基基团,由2至4个碳原子组成的炔基基团,苯基,卤素取代的苯基,或其对映体或药学上适用的盐,表现出对多巴胺D-2受体的高阻断活性和特异性。
  • [EN] CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS<br/>[FR] COMPOSÉS DE CARBOXAMIDE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA CALPAÏNE
    申请人:ABBOTT GMBH & CO KG
    公开号:WO2010128102A1
    公开(公告)日:2010-11-11
    The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula (I) in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula (Ia) and (Ib) in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2-CH2, CH2-CH2-CH2, N(Ry#)-CH2, N(Ry#)-CH2-CH2 or CH=CH-CH=, each optionally having 1 or 2 H-atoms replaced with identical or different radicals Ry, wherein Ry and Ry# have the meanings mentioned in the claims.
    本发明涉及新型羧酰胺化合物及其用于制备药物的用途。这些羧酰胺化合物是钙蛋白酶(依赖于的半胱蛋白酶)的抑制剂。因此,该发明还涉及利用这些羧酰胺化合物治疗与升高的钙蛋白酶活性相关的疾病。这些羧酰胺化合物是通式(I)的化合物,其中R1、R2、R3a、R3b、R4、Q、Y、A和X具有权利要求和说明中提及的含义,以及它们的互变异构体和药用盐。特别地,这些化合物具有通式(Ia)和(Ib),其中R1、r、R2b、R3a、R3b、R4、Y和X具有权利要求中提及的含义,包括它们的互变异构体和药用盐。在这些化合物中,首选Y是一个基团CH2- 、 - - 、N(Ry#)- 、N(Ry#)- - 或CH=CH-CH=,每个基团可选择地用1或2个氢原子替换为相同或不同的基团Ry,其中Ry和Ry#具有权利要求中提到的含义。
  • CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS
    申请人:Mack Helmut
    公开号:US20110086879A1
    公开(公告)日:2011-04-14
    The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R 1 , R 2 , R 3a , R 3b , R 4 , Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R 1 , r, R 2b , R 3a , R 3b , R 4 , Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH 2 —CH 2 , CH 2 —CH 2 —CH 2 , N(R y# )—CH 2 , N(R y# )—CH 2 —CH 2 or CH═CH—CH═, each optionally having 1 or 2 H-atoms replaced with identical or different radicals R y , wherein R y and R y# have the meanings mentioned in the claims.
    本发明涉及新型羧酰胺化合物及其用于制备药物的用途。这些羧酰胺化合物是依赖性半胱蛋白酶(calpain)的抑制剂。因此,本发明还涉及使用这些羧酰胺化合物治疗与升高的calpain活性相关的疾病。这些羧酰胺化合物是通式I的化合物,其中R1、R2、R3a、R3b、R4、Q、Y、A和X具有所述权利要求和说明书中提到的含义,它们的互变异构体和药学上适用的盐。特别是,化合物具有通式Ia和Ib,其中R1、r、R2b、R3a、R3b、R4、Y和X具有所述权利要求中提到的含义,包括其互变异构体和药学上适用的盐。其中,首选Y是CH2- 、 - - 、N(Ry#)- 、N(Ry#)- - 或CH=CH-CH=的基团,每个基团可选择性地用相同或不同的基团Ry替换1或2个氢原子,其中Ry和Ry#具有所述权利要求中提到的含义。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸